Arcutis Biotherapeutics (ARQT) Receivables: 2022-2025
Historic Receivables for Arcutis Biotherapeutics (ARQT) over the last 3 years, with Sep 2025 value amounting to $115.1 million.
- Arcutis Biotherapeutics' Receivables rose 91.48% to $115.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $380.3 million, marking a year-over-year increase of 128.41%. This contributed to the annual value of $73.1 million for FY2024, which is 183.12% up from last year.
- Per Arcutis Biotherapeutics' latest filing, its Receivables stood at $115.1 million for Q3 2025, which was up 7.90% from $106.7 million recorded in Q2 2025.
- Arcutis Biotherapeutics' 5-year Receivables high stood at $115.1 million for Q3 2025, and its period low was $2.4 million during Q3 2022.
- Its 3-year average for Receivables is $54.2 million, with a median of $43.4 million in 2024.
- Data for Arcutis Biotherapeutics' Receivables shows a peak YoY surged of 698.72% (in 2023) over the last 5 years.
- Arcutis Biotherapeutics' Receivables (Quarterly) stood at $8.5 million in 2022, then spiked by 205.12% to $25.8 million in 2023, then soared by 183.12% to $73.1 million in 2024, then spiked by 91.48% to $115.1 million in 2025.
- Its last three reported values are $115.1 million in Q3 2025, $106.7 million for Q2 2025, and $85.4 million during Q1 2025.